TY - JOUR T1 - Anti-interleukin 5 strategies as a potential treatment for asthma. JF - Thorax JO - Thorax SP - 483 LP - 485 DO - 10.1136/thx.52.5.483 VL - 52 IS - 5 AU - A D Singh AU - C J Sanderson Y1 - 1997/05/01 UR - http://thorax.bmj.com/content/52/5/483.abstract N2 - A paradigm shift, championed largely by cellular immunologists, has redefined asthma as an immune mediated phenomenon characterised by an interleukin 5 (IL-5) driven eosinophilic bronchitis. This change in emphasis has provoked intense interest in the possibility that inhibitors of IL-5 production, or antagonists of its activity, will provide a new generation of anti-asthma drugs. ER -